Vanda Pharmaceuticals earns from Fanapt, Hetlioz, and Ponvory sales. It aims to diversify its portfolio with pipeline candidates like tradipitant and milsaperidone. Vanda's focus on R&D and FDA approvals is expected to drive long-term growth.